I agree with you, although I have a significant long position, its the sheer stupidity , ignorance and bullying tactics aka cowardice of the longs here that worries me the most about this stock. I really do not want to be long a stock that these people are long but what can you do.
The stock will go up regardless if the results are good with the Dr. and LG collecting the vast share of the loot. The public shareholders will also get their crumbs.
The only reason LG and the doctor are in this stock because they will become rich from this. There is no other reason for LG to be involved otherwise.
The good doctor couldn't care less about your letter.
In case you have not figured it out this is a shell company with the good doctor and LG owning about 90% of the company. The majority of public shareholders are mostly uneducated, naïve and clueless cheerleaders.The doctor does the minimum necessary to maintain the fig leaf of being a public company.
I am not even sure why this company is public.
You can find the list of participating centers from list of trials. Once you contact the nearest center they will tell you who are the participating physicians. You might be cutting it close, typically NYMX announces the results before their shareholder meeting which is next Friday.
Maybe you don't read well. I said look it up yourself as I am tired of your nonsensical posts. It is obvious you have nothing to do but shoot breeze.
Step1. Start your internet
Step2. Go to the Sophiris web site
From My Previous Post in January. Look up the exact numbers yourself. The information is on the net.
"If AUA is subjective then the best objective indicator is an improvement in Qmax and in this category NX1207 shines. Flomax gets an average improvement of 1.5ml/sec and NX1207 gets an improvement of around 2.6ml/sec. Even the Sophiris product does not get such an improvement in the Qmax with similar/ lesser improvements in the AUA score."
The Sophiris drug is not as good as the Nymox drug. The Q max which is the only objective measure of improving urine flow is much better for Nymox.
You misunderstand me. With good phase three results the stock will probably be valued around 2 billion and that is where the majority of long term holders will sell and there will be an influx of new shareholders who will likely wait for the company to be finally sold and when its sold it will be IMO at least a ten billion dollar tag. The trick if the results are good is to be patient and not sell immediately..
This is a real and and a very conservative estimate. Do a google search and see what price promising biotech companies are sold at. Why will the CA indication be off label; its easy to make a case for the drug if you have good results in phase three as opposed to watchful waiting.
There are things to dislike about the company but if the results are good any big US hedge fund will gladly buy it out for 10 billion; hoping to resell it at a higher price.
I agree, Listened to it too and was pleasantly surprised by his demeanor. The prostate CA indication seems doable too. Approximately 50% of low grade localized cancer progress to a higher grade and spread. If this prevents/delays it is another huge indication; right now watching and waiting is the usual course of action.
I agree with a lot of what you say but disagree with your sale price projection. Pfizer recently bought a company with some promising drug in stage two for prostate cancer and the price was 10 billion. I think if the BPH indication is successful we are looking at least that.
Don't worry about johncock or bowbow; they are ignorant,mindless cheerleaders who can not see beyond the obvious; anybody who looks at NYMX critically is a short.
Nymx does not need a partner,IMO. It needs to be sold once all the results are out. I only hope it gets sold before Dr. A decides to go on his own for FDA approval. Regarding the prostate cancer results they seem promising but I hope a phase three trial protocol addresses the obvious problem with biopsy localization
Those days are long gone. Newly discovered biologics are being approved regularly. Recently FDA came out a with a statement on how it wants to expedite review of new biologics. The times are changing; the only thing that never changes is NYMX and Dr A. with constant paranoia, obfuscation and out right lies and blatant disregard of shareholder rights.
Assuming even if that is the case that does not explain the delay. If what you are saying is true DMC would grant a continue and recommend more trial subjects be recruited. It does not explain the delay unless you think NWBO is hiding the news.
Good Luck! I agree the company is not run professionally but hopefully this is more a function of Dr. A's personality rather than a problem with the drug.
In the conference call they stated they might not have to recruit 338 patients that it was events driven. Anybody with more statistical knowledge care to speculate as to how many additional patients they will have to implant; assuming similar results as in the past.